← Back to Search

Device

tDCS + Cognitive Training for Alzheimer's Disease

N/A
Recruiting
Led By John R McCarten, MD
Research Sponsored by Minneapolis Veterans Affairs Medical Center
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Participants demonstrating capacity to provide informed consent
Participants aged 60 or older
Timeline
Screening 3 weeks
Treatment Varies
Follow Up change between baseline and 3 week follow-up; 3 and 6 months following study baseline

Summary

This trial proposes a new treatment for early Alzheimer's that combines electrical stimulation with cognitive training to improve brain function & cognition.

Who is the study for?
This trial is for people aged 60 or older with early Alzheimer's disease (AD), mild cognitive impairment (MCI), or Mild Neurocognitive Disorder. They must be stable on medications, able to consent, have WiFi at home, and a care partner available for support. It excludes those with significant medical risks, other psychiatric/neurological conditions affecting cognition, scalp issues that could react to stimulation, or metal in the head.
What is being tested?
The study tests if brain stimulation called tDCS can improve thinking and brain function in patients with MCI and early AD. Participants will receive either active tDCS or a sham (fake) treatment alongside cognitive training exercises designed to boost executive functions.
What are the potential side effects?
tDCS may cause discomfort at the site of application on the scalp like itching or tingling during treatment. There might also be fatigue or headaches after sessions but these are generally mild and temporary.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I understand the details of the clinical trial and can consent to participate.
Select...
I am 60 years old or older.
Select...
I have been diagnosed with early Alzheimer's or mild cognitive impairment.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~change between baseline and 3 week follow-up; 3 and 6 months following study baseline
This trial's timeline: 3 weeks for screening, Varies for treatment, and change between baseline and 3 week follow-up; 3 and 6 months following study baseline for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Change in Brief Test of Adult Cognition by Telephone (BTACT)

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Active tDCSExperimental Treatment1 Intervention
Participants will receive 10 sessions of cognitive training concurrent with transcranial direct current stimulation (anode over left frontal cortex, cathode over right frontal cortex; 2 mAmps for 20 minutes).
Group II: Sham tDCSPlacebo Group1 Intervention
Participants will receive 10 sessions of cognitive training concurrent with sham tDCS. For sham tDCS, electrodes are placed at the same locations as for active tDCS, but current is ramped up for the initial 30 secs, then immediately ramped back down. This ramp up/down method is done at the end of the stimulation period, as well. This method mimics the physical sensation of stimulation typically encountered at the very beginning and end of the intervention period.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Active Transcranial Direct Current Stimulation (tDCS)
2020
N/A
~160

Find a Location

Who is running the clinical trial?

Minneapolis Veterans Affairs Medical CenterLead Sponsor
76 Previous Clinical Trials
16,247 Total Patients Enrolled
John R McCarten, MDPrincipal InvestigatorMinneapolis Veterans Affairs Medical Center

Media Library

Active Transcranial Direct Current Stimulation (tDCS) (Device) Clinical Trial Eligibility Overview. Trial Name: NCT04507815 — N/A
Alzheimer's Disease Research Study Groups: Sham tDCS, Active tDCS
Alzheimer's Disease Clinical Trial 2023: Active Transcranial Direct Current Stimulation (tDCS) Highlights & Side Effects. Trial Name: NCT04507815 — N/A
Active Transcranial Direct Current Stimulation (tDCS) (Device) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04507815 — N/A
~10 spots leftby Nov 2025